[{"NetIncomeLossConverted_1_Q2_USD":-56273000.0,"NetIncomeLossConverted_2_Q2_USD":-91777000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_2_Q2_USD":-58069000.0,"CommonStockSharesOutstanding_0_Q2_shares":49391738.0,"StockholdersEquity_0_Q2_USD":1067507000.0,"EarningsPerShareBasic_1_Q2_USD":-1.14,"EarningsPerShareBasic_2_Q2_USD":-1.87,"RevenuesConverted_1_Q2_USD":5164000.0,"RevenuesConverted_2_Q2_USD":30369000.0,"Assets_0_Q2_USD":1102920000.0,"CommonStockSharesConverted_0_Q2_shares":49391738.0,"Ticker":"TPTX","CIK":"1595893","name":"TURNING POINT THERAPEUTICS, INC.","OfficialName":"Turning Point Therapeutics Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"1579986704.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210809"}]